Comparative Pharmacology
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE W HYDRALAZINE versus TRICHLORMETHIAZIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: HYDROCHLOROTHIAZIDE W HYDRALAZINE versus TRICHLORMETHIAZIDE.
HYDROCHLOROTHIAZIDE W/ HYDRALAZINE vs TRICHLORMETHIAZIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Hydrochlorothiazide inhibits the Na+/Cl- symporter in the distal convoluted tubule, reducing sodium and water reabsorption. Hydralazine directly relaxes arteriolar smooth muscle via mechanisms involving nitric oxide, leading to vasodilation.
Inhibits sodium-chloride symporter in distal convoluted tubule, increasing excretion of sodium, chloride, and water.
Oral: hydrochlorothiazide 25-50 mg plus hydralazine 25-100 mg, twice daily; maximum hydralazine 300 mg/day.
2-4 mg orally once daily; maximum 4 mg/day.
None Documented
None Documented
Hydrochlorothiazide: 6-15 hours (terminal, prolonged in renal impairment); Hydralazine: 2-4 hours (fast acetylators), 4-8 hours (slow acetylators); clinical context: slow acetylators have higher risk of lupus-like reactions.
Clinical Note
moderateTrichlormethiazide + Digoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digoxin."
Clinical Note
moderateTrichlormethiazide + Digitoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Digitoxin."
Clinical Note
moderateTrichlormethiazide + Deslanoside
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Deslanoside."
Clinical Note
moderateTerminal elimination half-life is approximately 2-6 hours (average 3.5 h); clinical context: short half-life necessitates once or twice daily dosing for sustained diuresis.
Hydrochlorothiazide: ~70% renal (unchanged), 30% metabolized with metabolites excreted renally; Hydralazine: 80-90% renal (metabolites), <10% unchanged, some biliary/fecal.
Primarily renal (tubular secretion); ~70% excreted unchanged in urine; minor biliary/fecal (<10% total).
Category A/B
Category C
Thiazide Diuretic
Thiazide Diuretic
Trichlormethiazide + Acetyldigitoxin
"The risk or severity of adverse effects can be increased when Trichlormethiazide is combined with Acetyldigitoxin."